20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform
Natera, Inc. (NTRA)
Last natera, inc. earnings: 2/26 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.natera.com
Company Research
Source: Business Wire
Data from 75,000 patients underscore advances in AI-driven virtual genomics, Signatera™-guided treatment monitoring, and continued expansion of MRD and other capabilities AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA) a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts, including two oral presentations, featuring data generated using its technologies will be presented at the 2026 American Association for Cancer Research® (AACR) Annual Meeting 2026, taking place April 17–22 in San Diego, CA.These presentations, developed in collaboration with leading academic and clinical partners, span multiple tumor types and applications, including artificial intelligence, digital pathology, molecular residual disease (MRD) and real-world evidence (RWE).“These presentations reflect both the scale of our platform and the pace of innovation we’re driving across oncology,” said Alexey Aleshin, M.D., corporate chief medical officer and general manag
Show less
Read more
Impact Snapshot
Event Time:
NTRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTRA alerts
High impacting Natera, Inc. news events
Weekly update
A roundup of the hottest topics
NTRA
News
- Natera (NTRA) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=NTRA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "buy" to "hold".MarketBeat
- SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo SurgeryBusiness Wire
- Natera (NTRA) Launches Zenith Genomic Assay [Yahoo! Finance]Yahoo! Finance
- Natera Looks Compelling As Oncology Testing Momentum Keeps Building [Seeking Alpha]Seeking Alpha
- Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal CancersBusiness Wire
NTRA
Earnings
- 2/26/26 - Miss
NTRA
Sec Filings
- 4/3/26 - Form 4
- 4/3/26 - Form 4
- 4/1/26 - Form 4
- NTRA's page on the SEC website